acalabrutinib + obinutuzumab

Acalabrutinib + obinutuzumab is a combination therapy used primarily for the treatment of chronic lymphocytic leukemia (CLL), both in treatment-naive and relapsed/refractory patients. **Acalabrutinib** is a highly selective, covalent inhibitor of Bruton tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling, leading to inhibition of malignant B-cell proliferation. **Obinutuzumab** is a glycoengineered, type II anti-CD20 monoclonal antibody that induces direct cell death and enhances antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. The combination leverages the high BTK selectivity of acalabrutinib—which preserves immune-effector function—and the potent immune-mediated mechanisms of obinutuzumab to produce deep and durable remissions. The regimen has demonstrated improved progression-free survival, overall survival, and higher complete remission rates compared to chemoimmunotherapy and acalabrutinib monotherapy in CLL, including in high-risk genomic subgroups[1][2][3][5].